- contact@sekkeibio.com
Programs
- Program
- Indication
- Design
- Discovery
- Preclinical
- Phase 1
- Program
- Indication
- type
- Design
- Discovery
- PreClinical
- PHASE 1/2
- PARTNERSHIP
Novel Insulin :
oral pill*
oral pill*
Novel Insulin:
injectable
Oral
Incretin*
Incretin*
Thermostable
insulin
Insulin
-Glp1
-Glp1
peptide analgesic*
Multi-agonist incretin RNA
Women’s
health*
health*
RNA
vaccine*
vaccine*
Diabetes &
Obesity
Diabetic Complications,
Obesity
Contraception
Viral Infection
Biologics
RNA
NCE
RNA
Pharma partner
*Program have linked information
Novel Insulin : oral pill
Novel Insulin:
injectable
Oral Incretin
Thermostable insulin
Insulin-Glp1
Dual acting peptide analgesic
Multi-agonist incretin RNA
Women’s health
RNA Candidate vaccine
Biologics : For
Diabetes,
Obesity
Diabetes,
Obesity
Diabetes Complication Diabetes,
Obesity
Obesity
Contraception
Viral vaccine
Pharma partner
Oral Insulin
Sekkei Bio is developing innovative oral insulin to transform diabetes care. Current injectable insulin faces issues with patient discomfort and noncompliance. Sekkei Bio's novel approach uses in-silico tools and a streamlined process to design insulin for oral delivery. This breakthrough holds the potential to provide stable glucose control, reduce long-term complications, and greatly improve patient quality of life by offering a more convenient, non-invasive alternative to injections.
Oral Incretin
Obesity is a growing global crisis, with over 300 million obese adults worldwide. Incretin hormones in the gut play a crucial role in regulating metabolism, making them a valuable target for obesity and type 2 diabetes management. Semaglutide and Tirzepatide, FDA-approved incretin-based treatments, offer benefits like reduced body fat and improved cardiovascular health. Sekkei Bio is working to develop alternative oral incretin solutions.
Non-Opiate Analgesic
Sekkei Bio is developing innovative, non-opioid analgesics to address the global opioid crisis. Widespread opioid painkiller use has led to devastating addiction issues. Sekkei Bio's first-in-class approach targets multiple non-opioid pathways to provide safe, effective, and non-addictive solutions for acute and chronic pain, including painful diabetic neuropathy. By offering alternatives to opioids, Sekkei Bio aims to transform pain management and improve patient outcomes.
Non-Hormonal Contraceptive
Sekkei Bio is developing innovative, non-hormonal contraceptives (NHCs) to address the issues with hormonal birth control. Recent breakthroughs have identified new targets for NHC development. Using its proprietary Sq-Suite platform, Sekkei Bio is leveraging the Sq-SYNT module to discover effective, non-hormonal contraceptive solutions.
As part of the global NHC consortium and the Global Health Discovery Collaboratory, Sekkei Bio is pioneering safer, side-effect-free contraceptive alternatives to empower women's reproductive health.
RSV Vaccine
Sekkei Bio is developing a circular RNA vaccine to combat respiratory syncytial virus (RSV), a serious illness for infants and older adults. While recent subunit RSV vaccines have been approved, Sekkei Bio's innovative circular RNA approach aims to further advance RSV prevention by encoding a novel antigen, reducing costs and dosage, and potentially increasing protection duration - making it a globally relevant solution to this public health challenge.
Oral Insulin
Sekkei Bio is developing innovative oral insulin to transform diabetes care. Current injectable insulin faces issues with patient discomfort and noncompliance. Sekkei Bio's novel approach uses in-silico tools and a streamlined process to design insulin for oral delivery. This breakthrough holds the potential to provide stable glucose control, reduce long-term complications, and greatly improve patient quality of life by offering a more convenient, non-invasive alternative to injections.
Oral Incretin
Obesity is a growing global crisis, with over 300 million obese adults worldwide. Incretin hormones in the gut play a crucial role in regulating metabolism, making them a valuable target for obesity and type 2 diabetes management. Semaglutide and Tirzepatide, FDA-approved incretin-based treatments, offer benefits like reduced body fat and improved cardiovascular health. Sekkei Bio is working to develop alternative oral incretin solutions.
Non-Opiate Analgesic
Sekkei Bio is developing innovative, non-opioid analgesics to address the global opioid crisis. Widespread opioid painkiller use has led to devastating addiction issues. Sekkei Bio's first-in-class approach targets multiple non-opioid pathways to provide safe, effective, and non-addictive solutions for acute and chronic pain, including painful diabetic neuropathy. By offering alternatives to opioids, Sekkei Bio aims to transform pain management and improve patient outcomes.
Non-Hormonal Contraceptive
Sekkei Bio is developing innovative, non-hormonal contraceptives (NHCs) to address the issues with hormonal birth control. Recent breakthroughs have identified new targets for NHC development. Using its proprietary Sq-Suite platform, Sekkei Bio is leveraging the Sq-SYNT module to discover effective, non-hormonal contraceptive solutions.
As part of the global NHC consortium and the Global Health Discovery Collaboratory, Sekkei Bio is pioneering safer, side-effect-free contraceptive alternatives to empower women's reproductive health.
RSV Vaccine
Sekkei Bio is developing a circular RNA vaccine to combat respiratory syncytial virus (RSV), a serious illness for infants and older adults. While recent subunit RSV vaccines have been approved, Sekkei Bio's innovative circular RNA approach aims to further advance RSV prevention by encoding a novel antigen, reducing costs and dosage, and potentially increasing protection duration - making it a globally relevant solution to this public health challenge.
Oral Incretin
Obesity is an escalating global epidemic. Currently, there were over 300 million obese adults worldwide. Obesity is central to risks for diet-related noncommunicable diseases, including diabetes, cardiovascular disease, hypertension, stroke, and certain cancers. Incretin hormones in the gut play crucial role in glucose and fat metabolism and finds use in obesity and type 2 diabetes.. Semaglutide, an approved GLP1 receptor agonist, aids in weight management by reducing body fat, offers cardiovascular benefits and reduces inflammation. Recently, the FDA approved Tirzepatide, a dual agonist for GLP-1 and GIP receptors. Sekkei Bio is applying its formulation technology to develop alternative oral incretin solutions.
Non-Opiate Analgesic
The widespread use of opioid analgesics has resulted in addiction-driven crises across multiple geographies. The problems are further exacerbated by the use of opioids for conditions where they are ineffective such as neuropathies. Sekkei Bio is working on the development of first-in-class, non-opioid analgesic with molecules that specifically (by design) modulate multiple non-opioid pathways. The program aims to deliver safe, efficacious, and non-addictive solutions for the treatment of both acute and chronic pain conditions including painful diabetic neuropathy, which is one of the major complications of diabetes.
Non-Hormonal Contraceptive
The use of hormonal contraceptives presents significant issues, including side effects such as mood swings, weight gain, nausea, headaches, and an increased risk of blood clots. These side-effects along with the still significant rates of unplanned pregnancies, have highlighted the need for safe, effective non-hormonal contraceptives (NHCs). Recent breakthroughs in reproductive biology have allowed the identification of new targets towards the development of NHCs. Sekkei Bio is using the Sq-SYNT module (small molecule design module) within our proprietary Sq-Suite platform to identify ligands against newly identified targets. We are members of the global NHC consortium and Global health discovery Collaboratory (https://ghdiscoverycollaboratory.org/).
RSV Vaccine
Respiratory syncytial virus, or RSV, is a common respiratory virus that causes cold-like symptoms. It could prove to be serious in infants and older adults. In 2022, it was reported that there were approximately 61,86,500 episodes of RSV-associated acute lower respiratory infection in children below five years. Two subunit vaccines Arexvy (GSK), and Abrysvo (Pfizer), were approved by the FDA in May 2023 with an investigational RSV mRNA (linear RNA) vaccine developed by Moderna meeting the primary efficacy endpoints of phase III studies. Sekkei Bio is developing a globally-relevant circular RNA vaccine that encodes a novel RSV antigen with a focus on reducing the cost and dosage, and potentially increasing the duration of protection.
Multi-Agonist Incretins
Incretins are metabolic hormones that lower blood glucose levels, used in treating type 2 diabetes. The incretin mimetics market, valued at USD 22.7 billion in 2024, is projected to reach USD 31.5 billion by 2031. Key incretin-based medicines include DPP-4 inhibitors (e.g., Sitagliptin, Saxagliptin) and GLP-1 analogs (e.g., Exenatide, Liraglutide). Recently, the FDA approved Tirzepatide, a dual agonist for GLP-1 and GIP receptors.
At Sekkei Bio, we’re developing multi-agonist incretins as circular RNAs, promising longer action, cost-effectiveness, and physiological accuracy. Oral incretin delivery offers a non-invasive alternative to injections, enhancing patient compliance and glycemic control. Our innovative formulations protect incretin hormones from gastrointestinal degradation, ensuring sustained and controlled release for optimal therapeutic outcomes in diabetes treatment.
Sekkei Bio is seeking innovation partners to build
pharmaceutical technologies to revolutionize patient care.
pharmaceutical technologies to revolutionize patient care.